Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/14/2026 has been entered.
Response to Amendment
Claims 1-10 are pending.
The previous rejection of claims 1-4, 6, and 8 under 35 U.S.C. 102(a)(1) as being anticipated by Lee et al. (KR20130129543) is withdrawn in view of applicant’s amendment.
Terminal Disclaimer
The terminal disclaimer filed on 11/13/2025 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patent 12,563,963 and 12,161,044 have been reviewed and accepted. The terminal disclaimer has been recorded.
The previous rejection of claims 1-10 on the ground of non-statutory double patenting as being unpatentable over claims 1-6 and 9-11 of U.S. Patent No. 12,563,963 and 12,161,044 are withdrawn in view of the Terminal Disclaimer.
Claim Rejections - 35 USC § 102
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claim 9 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chun et al. (US2014/0048792).
Chun discloses the following compounds that read on the claimed compounds listed in claim 9.
PNG
media_image1.png
221
260
media_image1.png
Greyscale
PNG
media_image2.png
253
258
media_image2.png
Greyscale
PNG
media_image3.png
234
266
media_image3.png
Greyscale
Allowable Subject Matter
Claims 1-8 and 10 are allowed.
The following is a statement of reasons for the indication of allowable subject matter:
The compounds represented by the general formula (I), the specific compounds of claim 10 are not disclosed in the prior art.
The claimed compounds wherein the two alkyl and one aryl group are bonded to the phosphorus atom reduce operating voltage and improve external quantum efficiency and lifetime in organic light-emitting diodes, in particular in fluorescent blue devices.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to HAIDUNG D NGUYEN whose telephone number is (571)270-5455. The examiner can normally be reached M-Th: 10a-3p.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached on 571-272-2817. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/HAIDUNG D NGUYEN/Primary Examiner, Art Unit 1761
9/19/2026
Prosecution Insights